Is there an optimal prostate-specific antigen threshold for prostate biopsy?

References

• Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology54, 220–224 (1999).
   Google Scholar
• Schroder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr. Opin. Urol.19, 227–231 (2009).
   Google Scholar
• Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med.350, 2239–2246 (2004).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J. Urol.162, 293–306 (1999).
   PubMed Web of Science ®Google Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer8, 268–278 (2008).
   PubMed Web of Science ®Google Scholar
• Andriole GL, Grubb RL III, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med.360, 1310–1319 (2009).
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med.360, 1320–1328 (2009).
   PubMed Web of Science ®Google Scholar
• Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J. Am. Board Fam. Pract.16, 95–101 (2003).
   PubMedGoogle Scholar
• Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA273, 289–294 (1995).
   PubMed Web of Science ®Google Scholar
• Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch. Intern. Med.165, 1857–1861 (2005).
   Google Scholar
• Lilja H, Ulmert D, Bjork T et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J. Clin. Oncol.25, 431–436 (2007).
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol.151, 1283–1290 (1994).
   PubMed Web of Science ®Google Scholar
• Ahyai SA, Graefen M, Steuber T et al. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Eur. Urol.53, 750–757 (2008).
   PubMedGoogle Scholar
• Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J. Urol.172, 90–93 (2004).
   Google Scholar
• Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schroder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate39, 316–322 (1999).
   PubMedGoogle Scholar
• De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair SL, Semjonow A. Twenty years of PSA: from prostate antigen to tumor marker. Rev. Urol.9, 113–123 (2007).
   PubMedGoogle Scholar
• Sokoll LJ, Chan DW. Prostate-specific antigen. Its discovery and biochemical characteristics. Urol. Clin. North Am.24, 253–259 (1997).
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med.324, 1156–1161 (1991).
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Hudson MA, Scardino PT et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J. Urol.152, 2037–2042 (1994).
   PubMed Web of Science ®Google Scholar
• Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA277, 1456–1460 (1997).
   PubMed Web of Science ®Google Scholar
• Luboldt HJ, Bex A, Swoboda A, Husing J, Rubben H. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff. Eur. Urol.39, 131–137 (2001).
   Google Scholar
• Kuwahara M, Tochigi T, Kawamura S et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. Urology61, 137–141 (2003).
   PubMed Web of Science ®Google Scholar
• Schroder FH, Roobol-Bouts M, Vis AN, van der KT, Kranse R. Prostate-specific antigen-based early detection of prostate cancer – validation of screening without rectal examination. Urology57, 83–90 (2001).
   PubMed Web of Science ®Google Scholar
• Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol.172, 1297–1301 (2004).
   PubMed Web of Science ®Google Scholar
• Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett.249, 30–39 (2007).
   PubMed Web of Science ®Google Scholar
• Roddam AW, Price CP, Allen NE, Ward AM. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin. Chem.50, 1012–1016 (2004).
   Google Scholar
• Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin. Chem.52, 59–64 (2006).
   PubMed Web of Science ®Google Scholar
• Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin. Chem.52, 1568–1574 (2006).
   PubMed Web of Science ®Google Scholar
• Link RE, Shariat SF, Nguyen CV et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J. Urol.171, 2234–2238 (2004).
   PubMed Web of Science ®Google Scholar
• Semjonow A, Oberpenning F, Weining C et al. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin. Chem.47, 1472–1475 (2001).
   Google Scholar
• Soletormos G, Semjonow A, Sibley PE et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin. Chem.51, 1342–1351 (2005).
   PubMedGoogle Scholar
• Singh R, Cahill D, Popert R, O’Brien TS. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int.92, 932–935 (2003).
   Web of Science ®Google Scholar
• Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J. Urol.155, 3–9 (1996).
   PubMed Web of Science ®Google Scholar
• Banez LL, Hamilton RJ, Partin AW et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA298, 2275–2280 (2007).
   PubMed Web of Science ®Google Scholar
• Hekal IA, Ibrahiem EI. Obesity-PSA relationship: a new formula. Prostate Cancer Prostatic Dis.13, 186–190 (2010).
   Google Scholar
• Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur. Urol.49, 460–465 (2006).
   PubMedGoogle Scholar
• Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl Cancer Inst.98, 529–534 (2006).
   PubMed Web of Science ®Google Scholar
• Schroder FH, Carter HB, Wolters T et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur. Urol.53, 468–477 (2008).
   PubMed Web of Science ®Google Scholar
• Berger AP, Deibl M, Strasak A et al. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology69, 134–138 (2007).
   Google Scholar
• Loeb S, Roehl KA, Catalona WJ, Nadler RB. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J. Urol.177, 899–902 (2007).
   Google Scholar
• Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J. Urol.158, 1876–1878 (1997).
   Google Scholar
• Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology57, 476–480 (2001).
   Google Scholar
• Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J. Urol.174, 2191–2196 (2005).
   PubMed Web of Science ®Google Scholar
• Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol.147, 815–816 (1992).
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA270, 860–864 (1993).
   PubMed Web of Science ®Google Scholar
• Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol. Clin. North Am.20, 665–670 (1993).
   PubMed Web of Science ®Google Scholar
• Nixon RG, Brawer MK. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br. J. Urol.79(Suppl. 1), 61–67 (1997).
   Google Scholar
• Catalona WJ, Richie JP, deKernion JB et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol.152, 2031–2036 (1994).
   PubMed Web of Science ®Google Scholar
• Stephan C, Stroebel G, Heinau M et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/ml. Cancer104, 993–1003 (2005).
   Google Scholar
• Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur. Urol.58, 551–558 (2010).
   PubMed Web of Science ®Google Scholar
• Oliveira M, Marques V, Carvalho AP, Santos A. Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU Int.107(11), 1780–1783 (2011).
   Google Scholar
• Kranse R, Roobol M, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate68, 1674–1680 (2008).
   Google Scholar
• Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J. Urol.155, 1336–1339 (1996).
   PubMedGoogle Scholar
• Reissigl A, Pointner J, Horninger W et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology46, 662–665 (1995).
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA277, 1452–1455 (1997).
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Suburu R et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J. Urol.147, 846–851 (1992).
   PubMed Web of Science ®Google Scholar
• Gomez D, Lujan GM, Paez BA et al. [Detection of prostatic cancer in the PSA range between 3 and 3.9 ng/ml]. Actas Urol. Esp.26, 271–274 (2002).
   Google Scholar
• Hekal IA. The patients less than 50 years: is there a need to lower the PSA cutoff point? Prostate Cancer Prostatic Dis.12, 148–151 (2009).
   Google Scholar
• Sardana G, Dowell B, Diamandis EP. Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer. Clin. Chem.54, 1951–1960 (2008).
   PubMed Web of Science ®Google Scholar
• Stephan C, Rittenhouse H, Cammann H et al. New markers and multivariate models for prostate cancer detection. Anticancer Res.29, 2589–2600 (2009).
   PubMed Web of Science ®Google Scholar
• Spishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis.13, 12–19 (2010).
   Google Scholar
• Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA279, 1542–1547 (1998).
   PubMed Web of Science ®Google Scholar
• Sokoll LJ, Sanda MG, Feng Z et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev.19, 1193–1200 (2010).
   PubMed Web of Science ®Google Scholar
• Stephan C, Kahrs AM, Cammann H et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate69, 198–207 (2009).
   PubMedGoogle Scholar
• Haese A, de la TA, van PH et al. Clinical utility of the PCA3 urine assay in european men scheduled for repeat biopsy. Eur. Urol.54, 1081–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Schroder FH, van Leenders GL et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (>/=100). Eur. Urol.58(6), 893–899 (2010).
   PubMed Web of Science ®Google Scholar
• Groskopf J, Siddiqui J, Aubin SM et al. Feasibility and clinical utility of a TMPRSS2:ERG gene fusion urine test [Abstract]. Eur. Urol. (Suppl. 8), 195 (2009).
   Google Scholar
• Esgueva R, Perner S, LaFargue J et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod. Pathol.23, 539–546 (2010).
   PubMedGoogle Scholar
• Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur. Urol.54, 274–290 (2008).
   PubMed Web of Science ®Google Scholar
• Snow DC, Klein EA. Use of nomograms for early detection in prostate cancer. J. Natl Compr. Canc. Netw.8, 271–276 (2010).
   Google Scholar
• Chun FK, Briganti A, Graefen M et al. Development and external validation of an extended 10-core biopsy nomogram. Eur. Urol.52, 436–444 (2007).
   Google Scholar
• Karakiewicz PI, Benayoun S, Kattan MW et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J. Urol.173, 1930–1934 (2005).
   Web of Science ®Google Scholar
• Finne P, Finne R, Auvinen A et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology56, 418–422 (2000).
   PubMed Web of Science ®Google Scholar
• Stephan C, Cammann H, Meyer HA et al. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int.102, 799–805 (2008).
   Google Scholar
• Chun FK, de la TA, van PH et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol.56, 659–667 (2009).
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA270, 860–866 (1993).
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Loeb S. The PSA era is not over for prostate cancer. Eur. Urol.48, 541–545 (2005).
   PubMed Web of Science ®Google Scholar
• Chavan PR, Chavan SV, Chavan NR, Trivedi VD. Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study. J. Postgrad. Med.55, 17–21 (2009).
   Google Scholar
• Singh JC. Cut-off value for PSA: do we need a change? J. Postgrad. Med.55, 150–151 (2009).
   Google Scholar
• Heidenreich A, Bellmunt J, Bolla M et al. EAU Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol.59(1), 61–71 (2011).
   PubMed Web of Science ®Google Scholar
• Carroll P, Albertsen PC, Greene K et al. Prostate-specific antigen best practice statement: 2009 Update. American Urological Association Education and Research, Inc®1–81 (2009).
   Google Scholar
• Lawrentschuk N, Daljeet N, Ma C, Hersey K, Zlotta A, Fleshner N. Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist’s practice patterns. Int. Urol. Nephrol.43(1), 31–37 (2010).
   Google Scholar